Conference Coverage

Cardiotoxicity after checkpoint inhibitor treatment seen early, linked to elevated biomarkers



While immune checkpoint inhibitors were not significantly more cardiotoxic than other lung cancer treatments, major adverse cardiac events (MACE) did occur earlier, and occurred more frequently in patients with elevated biomarkers, in a retrospective cohort study reported at the annual scientific meeting of the Heart Failure Society of America.

Dr. Kalyan R. Chitturi, DeBakey Heart and Vascular Center, Houston Methodist Hospital Andrew D. Bowser/MDedge News

Dr. Kalyan R. Chitturi

The findings support monitoring of cardiac biomarkers in the initial phase of checkpoint inhibitor treatment to identify patient at high cardiac risk, according to Kalyan R. Chitturi, DO, a resident physician with the DeBakey Heart and Vascular Center, Houston Methodist Hospital, who presented the results.

“It’s the early period that warrants the closest monitoring, as within the first 30-40 days, there’s higher risk,” Dr. Chitturi said in an interview. “When there was a biomarker elevation, it markedly increased the risk of MACE, warranting a closer vigilance during that time period.”

The retrospective study conducted by Dr. Chitturi and colleagues included a total of 252 patients with lung cancer who had been treated at one of seven different sites in Houston Methodist Cancer Center between Aug. 1, 2015, and Aug. 1, 2018.

Immune checkpoint inhibitors did not significantly increase the risk of MACE, compared with other lung cancer therapies, with incidences of 13.3% and 10.3%, respectively (P = .632), the investigators found.

However, MACE did occur earlier in the checkpoint inhibitor group, at a median time to event of 40 days, compared with 118 days in the patients not treated with checkpoint inhibitors, they found.

Risk of MACE with checkpoint inhibitor treatment was increased in patients with elevated troponin (hazard ratio, 2.48; 95% confidence interval, 1.18-5.21; P = .017) or elevated brain natriuretic peptide (HR, 5.77; 95% CI, 2.70-12.35; P less than .001), according to multivariate logistic regression analysis results.

These results suggest biomarkers such as cardiac troponin and brain natriuretic peptide are warranted to monitor patients in the early phase of checkpoint inhibitor treatment, according to Dr. Chitturi. “In the cost-benefit ratio of often-lethal MACE, it’s well worth it to collect these,” he said in the interview.

The results corroborate findings from some other recent studies, he noted. These include a recent study that linked elevated serum troponin to myocarditis in patients treated with immune checkpoint inhibitors (J Am Coll Cardiol. 2018 Apr 24;71[16]:1755-64).

Dr. Chitturi and coauthors reported no disclosures related to their presentation at the HFSA meeting.

SOURCE: Chitturi KR et al. HFSA 2019, Abstract 127.

Recommended Reading

How thin should we go?
MDedge Cardiology
HCV coinfection adds to cardiovascular risk in HIV-infected patients
MDedge Cardiology
PCSK9 inhibition cuts events in very-high-risk groups
MDedge Cardiology
COMPLETE revascularization reduces death and recurrent MI risk
MDedge Cardiology
POP AGE shakes up DAPT in elderly
MDedge Cardiology
Early post-ACS bleeding may signal cancer
MDedge Cardiology
Post-MI angina in stable patients flags high risk
MDedge Cardiology
ISAR-REACT 5: Prasugrel superior to ticagrelor in ACS
MDedge Cardiology
Skip supplemental O2 in nonhypoxic ACS
MDedge Cardiology
Dual therapy best for AFib with ACS no matter the treatment strategy
MDedge Cardiology